Prosecution Insights
Last updated: October 02, 2026

Examiner: AGAHI, PUYA

Tech Center 3700 • Art Units: 3735 3791

This examiner grants 49% of resolved cases

Analysis

Puya Agahi is an examiner in Tech Center 3700 and Art Unit 3735, with 537 resolved cases. The examiner has an allowance rate of 49.2%, which suggests a challenging environment where fewer than half of the 537 cases result in a grant. This 49.2% rate indicates that practitioners should be prepared for a rigorous and potentially difficult prosecution. The data reflects a significant history of examination within this unit.

The interview lift is 24.4%, which is a substantial positive factor. This 24.4% lift suggests that direct communication with the examiner can significantly improve the chances of an allowance. The median days to allowance is 1529, indicating a long timeline for successful cases. This 1529-day median, combined with the 49.2% allowance rate, highlights the importance of using interviews to overcome rejections. Practitioners may find that the 24.4% lift is essential for navigating the 1529-day path to a successful outcome.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

49.2%
Allow Rate
-20.8% vs TC avg
592
Total Applications
+24.4%
Interview Lift
1529
Avg Prosecution Days
Based on 537 resolved cases, 2023–2026

Rejection Statute Breakdown

23.7%
§101 Eligibility
6.9%
§102 Novelty
40.9%
§103 Obviousness
22.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18192273 SYSTEMS AND METHODS FOR MISSED BREATH DETECTION AND INDICATION Non-Final OA Covidien LP
17520130 BIOLOGICAL DATA ACQUISITION APPARATUS AND BIOLOGICAL DATA PROCESSING APPARATUS USING THE SAME Final Rejection UIF (University Industry Foundation), Yonsei University
18306086 METHODS, DEVICES, AND SYSTEMS RELATED TO ANALYTE MONITORING Final Rejection Abbott Diabetes Care Inc.
15486948 SYSTEM FOR IN-VIVO MEASUREMENT OF AN ANALYTE CONCENTRATION Final Rejection ROCHE DIABETES CARE, INC.
18548767 DETECTION OF STAGE I LUNG CANCER BIOMARKERS Final Rejection THE JOHNS HOPKINS UNIVERSITY
18966643 BIOLOGICAL INFORMATION DETECTION SYSTEM Non-Final OA Murata Manufacturing Co., Ltd.
18814229 SENSOR AND TRANSMITTER PRODUCT Non-Final OA MEDTRONIC MINIMED, INC.
18527818 IN-VIVO ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY (EIS)-BASED CALIBRATION Non-Final OA Medtronic MiniMed, Inc.
18332552 ESTIMATING BLOOD PRESSURE OF A SUBJECT USING AN ECG DRIVEN CARDIOVASCULAR MODEL Final Rejection Tata Consultancy Services Limited
18689039 BLOOD COLLECTION SYSTEM AND BLOOD COLLECTION METHOD Final Rejection Hitachi, Ltd.
18192793 DEVICE AND METHOD FOR COLLECTING AND PROCESSING ELECTROMYOGRAPHY SIGNAL Non-Final OA SHENZHEN SHOKZ CO., LTD.
16802841 Systems and Methods For Improved Brain Monitoring During General Anesthesia And Sedation Non-Final OA The General Hospital Corporation
18535815 DEVICES, SYSTEMS, AND METHODS TO COMPENSATE FOR EFFECTS OF TEMPERATURE ON IMPLANTABLE SENSORS Final Rejection Dexcom, Inc.
19192024 CENTRAL AND MIXED SLEEP APNEA DETECTION Non-Final OA Huxley Medical, Inc.
18555339 POINT-OF-CARE PREDICTION OF MUSCLE RESPONSIVENESS TO THERAPY DURING NEUROREHABILITATION Non-Final OA UNIVERSITY HEALTH NETWORK
18636890 SCREENER FOR SLEEP DISORDERED BREATHING Non-Final OA ResMed Sensor Technologies Limited
18781632 RESPIRABLE AND THORACIC SAMPLING INLET ASSEMBLIES Non-Final OA Colorado State University Research Foundation
18032832 BIOMARKER FOR BLOOD ANOMALY Non-Final OA INDIAN INSTITUTE OF SCIENCE
18281489 METHOD FOR EXTRACTING RESPIRATORY INFORMATION FROM A BIO-IMPEDANCE SIGNAL Final Rejection Onera Technologies B.V.
18031567 AIR BORNE PATHOGENS DETECTION DEVICE Final Rejection Colin Hickey

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month